Financials
Financial year 2025
VERIPHARM from Mol, company number BE0475905160, closed financial year 2025 with a result of € 184,855 after tax. For that financial year VERIPHARM recorded a gross margin of € 170,272 and equity of € 885,230. Compared with financial year 2024, the result moved from € 36,189 to € 184,855. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 885,230
▲ 26% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 184,855
▲ € 148,666 vs 2024
Profit after tax over the fiscal year.
€ 75,443
▼ 31% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 623,730.
People and assets in 2025
€ 964
▼ 33% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 652,305
▼ 9% vs 2024
€ 58,011 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.
€ 1,193
▼ 27% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 8,854
▲ 217% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 132,866 | € 179,061 | € 162,523 | € 170,272 | ▲ 5% |
| Profit after taxes | € 18,013 | € 49,282 | € 36,189 | € 184,855 | ▲ € 148,666 |
| Equity | € 1,184,904 | € 1,234,186 | € 700,375 | € 885,230 | ▲ 26% |
| Total debts | € 946,544 | € 802,379 | € 1,293,437 | € 664,382 | ▼ 49% |
| Cash | € 157,120 | € 142,928 | € 109,285 | € 75,443 | ▼ 31% |
| Land & buildings | € 1,434,620 | € 1,366,144 | € 1,290,891 | € 1,196,108 | ▼ 7% |
| Retained profit | € 923,404 | € 972,686 | € 438,875 | € 623,730 | ▲ 42% |
| Dividend | € 30,000 | € 0 | € 570,000 | € 0 | ▼ 100% |
| Bank debt | € 869,839 | € 793,828 | € 717,816 | € 652,305 | ▼ 9% |
| Balance sheet total | € 2,131,449 | € 2,036,565 | € 1,993,812 | € 1,549,613 | ▼ 22% |
Key figures of VERIPHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to VERIPHARM?
What happened at VERIPHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Rita Verté stepped down as director. NBB
- Louis Verelst stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 184,855 (▲ € 148,666 vs 2024). Source: NBB ↗
- Rita Verté became a director. NBB
- Louis Verelst became a director. NBB
- New establishment in Mol. KBO
- Start of the company according to the CBE. KBO
In short
From € 18,013 profit in 2022 to € 184,855 profit in 2025.
Paid € 50,791 in corporate taxes since 2022.
Best year ever: 2025, with € 184,855 profit.
Paid out € 600,000 in dividends to the owners in total.
A new publication or filing at VERIPHARM? We notify you, reason included.
Follow VERIPHARMDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
since 2025 · until 2031
Louis Verelst
Director
since 2025 · until 2031
Establishments
Establishment units
Physical locations of this company
St.-Jozefslaan 55
2400 Mol
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Self-hosted
Hosting
LEASEWEB-NL-AMS-01 Netherlands, NL
Website info
Features
Security
Details
- Company number
- 0475.905.160
- VAT number
- BE 0475.905.160
- Registered office
- St.-Jozefslaan 55, 2400 Mol
- Names & denominations
- VERIPHARM
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 October 2001
- Peppol
- Active · Active since 27 Jan 2026
- Activities · NACE
Overige zakelijke dienstverlening, neg
Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen
Handel in eigen onroerend goed